Cells from the gut's nervous system found to be involved in Parkinson's disease
According to prof. Seledtsov, a person's immune system becomes hostile to the one it ought to protect, because of the logic shift, as it is now not aimed at keeping the "owner" alive but becomes aimed at the species survival, which means constant renewing, with the young replacing the old. Because renewing means adapting to changeable conditions. Thus these aging mechanisms keeps the human population safe by constantly stimulating adaptation. Can we lower the pathologic autoreactivity of the immune cells?
Viktor Seledtsov and Alexei von Delwig have offered a method of lymphocytic vaccination to counter autoimmune diseases. This technology is aimed at the natural autoimmune mechanism's stimulation. The method proved to be clinically effective in the treatment of multiple sclerosis and rheumatoid arthritis.
Prof. Seledtsov continued: "There is also an approach to counter the immunology aging, which is to create an immunology cell bank to keep immunocompetent cells extracted during a person's youth. When injected into an aging body, these cells are able to enhance immunological protection against infection, take control of "old" autoimmune cells and thus prolong a person's life. And a person's own cells are the best material for the injection. And to make this procedure possible, we need the immunology bank".
Seledtsov believes that a young person may give his immune cells to the bank and later inject those cells back to him upon reaching the age of 65, for example.
The technologies like this will not solve all human beings' health issues and will not grant immortality, but they may prolong life and improve living standards. Source:
Immanuel Kant Baltic Federal University Journal reference:
Seledtsov, V.I & von Delwig, A.A (2020) Immune memory limits human longevity: the role of memory СD4+ T cells in age-related immune abnormalities. Expert Review of Vaccines . doi.org/10.1080/14760584.2020.1745638 .
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology